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Abstract
Background: Rare Disease research has seen tremendous advancements over the last decades, with the development
of new technologies, various global collaborative efforts and improved data sharing. To maximize the impact of and to
further build on these developments, there is a need for model consent clauses for rare diseases research, in order to
improve data interoperability, to meet the informational needs of participants, and to ensure proper ethical and legal
use of data sources and participants’ overall protection.
Methods: A global Task Force was set up to develop model consent clauses specific to rare diseases research, that are
comprehensive, harmonized, readily accessible, and internationally applicable, facilitating the recruitment and consent
of rare disease research participants around the world. Existing consent forms and notices of consent were analyzed
and classified under different consent themes, which were used as background to develop the model consent clauses.
Results: The IRDiRC-GA4GH MCC Task Force met in September 2018, to discuss and design model consent clauses.
Based on analyzed consent forms, they listed generic core elements and designed the following rare disease research
specific core elements; Rare Disease Research Introductory Clause, Familial Participation, Audio/Visual Imaging, Collecting,
storing, sharing of rare disease data, Recontact for matching, Data Linkage, Return of Results to Family Members,
Incapacity/Death, and Benefits.
Conclusion: The model consent clauses presented in this article have been drafted to highlight consent elements that
bear in mind the trends in rare disease research, while providing a tool to help foster harmonization and collaborative
efforts.
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Background
Over the last decade, rare disease research has seen
tremendous developments in diagnostic efficiency and
therapeutic interventions [1]. Contributing factors in-
clude the discovery of novel genes with new sequen-
cing technologies, global collaborative efforts and
commitments, and improved data and resource shar-
ing. Adding to this are the growing number of geno-
type-phenotype datasets and matchmaking platforms,
along with the trend towards patient-centered re-
search, whereby patient organizations play a leading
role in data generation and research recruitment. To
maximize the impact of these initiatives in contribut-
ing substantive amounts of quality data for research
use, practical model consent clauses are essential to
enhance data interoperability as well as to meet the
informational needs of participants, ensure proper
ethical and legal use of data sources and participants’
overall protection.
To address this need, the International Rare Diseases
Research Consortium (IRDiRC) and the Global Alliance
for Genomics and Health (GA4GH) met to develop
model consent clauses for rare disease research. The
following proposed consent clauses are guided by the
Framework for Responsible Sharing of Genomics and
Health-Related Data [2] and other international and
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national ethics and legal consent frameworks. They
provide the foundation for the harmonization and
standardization of participant recruitment and consent
processes for rare disease research. Although not all the
proposed clauses are exclusive to the rare disease context,
certain clauses are of particular importance to consent
procedures for rare disease research and complement
existing core elements found in “classical” or “generic”
consent forms. It is hoped that together these clauses will
ensure that research involving patients with rare condi-
tions be deployed effectively to promote and catalyze
collaborative multinational studies through interoper-
able and responsible research practices endorsed by
IRDiRC and GA4GH.
Consent issues in rare disease research
Obtaining informed consent from research partici-
pants not only respects personal autonomy, self-deter-
mination, and the right to privacy but also seeks to
prevent undue harm [3–5]. Research participants
must be well informed of the research goals, benefits
and risks, and the possibility to refuse participation
and withdraw from research at any time without af-
fecting their medical care. The voluntary expression
of consent is fundamental to ethical research prac-
tices. In the rare disease research context, however,
consent processes have become complex in the
current landscape of technological and genomic ad-
vances, along with the extensive collection, pooling
and dissemination of data worldwide. Because of the
scarcity of patients and the need to share information
internationally to find similar cases, data sharing and
‘matchmaking’ is imperative for rare disease research.
Since most rare diseases appear in childhood, the re-
cruitment of children and unaffected family members
might further complicate consent processes [6]. Par-
ticular phenotypes of rare disease patients also often
require the collection and sharing of audiovisual data
(e.g., facial images, videos, etc.), the use of machine
learning procedures for data phenotyping [7], and the
bridging between clinical care and research [8] in this
scientific domain.
Notably, the challenge in establishing consent pol-
icies for rare disease research stems from the dichot-
omy between the push for free-flow of data against
concerns about loss of privacy. Patients with rare dis-
eases often expect that data are shared for scientific
advances in genomic medicine and rare diseases re-
search. At the same time, patients are concerned
about being identified, a risk inherent to data sharing
[9] and enhanced in the rare disease context. Particu-
larly, the likelihood of individual re-identification
from genomic data, whether coded or anonymized,
has been documented [10, 11], especially when such
data has been linked with other sensitive familial,
sociodemographic or audiovisual information. This is
why international policy approaches to assess privacy
risks in genomic research widely adopt as a criterion
the “reasonable likelihood test” (i.e., based on the pro-
portionate evaluation of real risks and benefits and
the balance of probabilities, the possible benefits for
participants must surpass potential consequences for
their privacy) [12].
The singularity and diversity of rare diseases, com-
bined with the small number of patients for each dis-
order, effectively precludes conventional research
discovery approaches, including those directed at ad-
dressing privacy risks and concerns. Some rare disease
research mandates cross-matching data between differ-
ent centers for discovery and diagnostic purposes. Thus,
absolute privacy protection is unrealistic in this realm.
Coding and security tools serve to mitigate and protect
against privacy risks. However, re-identification is
often desired by patients for the return of results and
so precludes anonymization [7, 13].
Hence, research involving rare disease participants
is challenged by unique realities and overall impedi-
ments to genomic research, and thus, should be ac-
knowledged in ethical and legal deliberations
regarding research protocols, privacy protections, and
consent standards. Rare disease participants are often
well informed about their disease, highly motivated to
participate in different research studies, and strong
advocates for greater access to research. They may
view identifiability risks as minor when weighed
against the opportunity to gain a diagnosis or to sup-
port research advancements towards new therapies.
Consequently, privacy interpretations should be
broadened to include not only the right to confidenti-
ality, secrecy and non-interference but also the posi-
tive right to “determine and manage personal
information, and to actively have a say in one’s own
private sphere” [14] and to realize the human right of
everyone to “share in scientific advancements and its
benefits [15, 16].” Moreover, privacy protections
should go beyond rare disease participants to also
protect and further the interests of their family mem-
bers in familial and trio genomic studies [17].
As such, the adoption of governance frameworks, se-
curity measures, and standards (i.e., data management/
access policies, Privacy Preserving Record Linkage [18]
or unique identifying systems) has become the nexus
from which privacy discourse has shifted [19]. Adding
to this is a move towards a nuanced approach to con-
sent standards that account for the unique complex-
ities and specificities of rare disease research [20]. By
obtaining proper informed consent, proportionality
between protecting the rights and interests of rare
Nguyen et al. BMC Medical Ethics           (2019) 20:55 Page 2 of 7
disease participants and promoting good research is
achievable. In fact, qualitative studies show that
knowledgeable rare disease patients understand the
need for large-scale data sharing and expect their data
to be distributed and reused but require, nonetheless,
that they be informed of such activities in order to
maintain a level of protection and control [21, 22].
Methods
In January 2018, a joint IRDiRC and GA4GH Model
Consent Clauses (MCC) Task Force was charged to
develop model consent clauses relevant to rare dis-
ease research. Both IRDiRC and GA4GH asked their
members to nominate members to the Task Force,
and the Chairs of the Task Force decided on the final
composition of the Task Force. The Task Force was
composed of 15 members from 8 different countries,
covering different expertise areas including law, eth-
ics, health policy, research and clinical experience.
Two members were representatives of patient organiza-
tions, e.g., Canadian Organization for Rare Disorders
(CORD) and the French Muscular Dystrophy Association
(AFM-Téléthon). The objective of the Task Force was to
create consent clauses that are comprehensive, har-
monized, readily accessible, and internationally applic-
able, facilitating the recruitment and consent of rare
disease research participants around the world. The
Scientific Secretariat of IRDiRC first reached out to
all IRDiRC Consortium Assembly members and all
Task Force members with the following question:
“In your work/experience or in the 'best case scenario,'
are there clauses you have used in rare disease
research consent forms that are not usually found or
should be found on generic biomedical research
forms?”
Five IRDiRC Consortium Assembly members and three
Task Force members were able to share their consent
forms and clauses, contributing to a total of 35 consent
forms and/or notice of consent. Additionally, 5 publica-
tions from the Clinical Sequencing Evidence-Generating
Research (CSER) and Electronic Medical Records and
Genomics (eMERGE) projects were analyzed [23–27].
The clauses were classified under different consent
themes and were used as references.
Results
In September 2018, the MCC Task Force met at the
Rare Disease Platform in Paris, France, to develop and
draft the model consent clauses (Additional file 1). The
meeting consisted of background presentations, iterating
the role and objectives of IRDiRC and GA4GH, as well
as provision of a historical overview of the evolution of
Table 1 Emerging Trends in Rare Disease Research with
Consent Implications
1. Increased complexity of research methods
• Researchers are increasingly exploring new approaches to identify
rare genetic variants resulting in increased complexity and diversity of
research methods and protocols;
• Clinical care often involves research in the context of specialty
clinics providing care for rare disease patients.
Consent implications:
• Consent forms risk becoming lengthy, technical and complicated;
• The study purpose and potential benefits must be clearly stated to
manage participant expectations and provide them with the
necessary information to make informed decisions.
2. Increased family enrollment as a unit
• Family members can provide important information in identifying
the cause of a rare genetic disease (increased diagnostic rate –
singleton vs. trio analysis) or help identify de novo mutations in a
family;
• Establishment of family pedigrees to allow linkage of family data.
Consent implications:
• Although each family member may undergo individual consent
interviews, often families are recruited using one consent document
to address ethical and administrative challenges (i.e., no distinction
made between “affected” and “unaffected” family members in
consent forms);
• Disclose privacy protections for use and sharing of family data;
• Address possible coercion or undue inducement from family
members participating in research study;
• Address the return of results to family members;
• Provide the possibility to notify family members of research results
in case of the participant’s incapacity or death.
3. Increased data collection (amount, type & frequency)
• Types of data collected: medical (e.g., clinical test results, diagnoses),
health (e.g., administrative, self-reported data, sociodemographic),
family history, genetic and phenotypic data;
• Data sources: hospitals, private clinics, research, registries, social
network sites;
• Ongoing data acquisition from medical records.
Consent implications:
• Disclose information, privacy and identifiability risks to participants
and their family members.
4. Increased use of audiovisual data
• 2–3 dimensional facial imaging used to identify and analyze patterns
and similarities associated with facial dysmorphology;
• Effective in identifying the underlying cause of rare diseases with
computational phenotyping.
Consent implications:
• Disclose information, privacy and identifiability risks to participants.
5. Increased global data sharing and linkage
• Global data sharing, data linkage and international collaboration
allow achieving sample sizes of statistical significance, richer datasets
and ability to “match” similar genotypes/phenotypes for gene
discovery in rare diseases;
• Data linkage minimizes the burden on participants to submit new or
additional data;
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consent forms used in rare disease research over the past
8–10 years, along with emerging trends (see Table 1).
The group identified different research themes that are
specific and crucial for rare disease research. Based on a
compilation of already existing consent form language,
the experts then developed Generic and Rare Disease Spe-
cific Core Consent Elements (Table 2) and Model Consent
Clauses for Rare Disease Research (Table 3) that take into
account international socio-ethical, legal and cultural dif-
ferences as well as keeping the patients’ perspectives in
mind.
The model consent clauses presented below serve as a
practical tool to assist in the development of consent
forms and research protocols. These clauses aim to
provide examples of consent categories that are specific
to rare disease research and therefore do not cover all
necessary components of a standard consent form
(see: Table 2: Generic and Core Consent Elements for
Rare Disease Research). Local laws, regional policy
and guidelines may extend or modify these consent
requirements and therefore variation can be expected.
In addition to the introductory consent clauses regard-
ing the purpose of the research, name of researchers/
sponsors etc., rare disease consent forms could use
introductory clauses to draw attention to some of the
unique features that distinguish it from the standard
core consent elements. These clauses must be custom-
ized to each project’s specific needs.
Discussion
Scientific breakthroughs in research and clinical fields
have brought immense opportunities for potential
diagnostic tools and therapies to those affected by a
rare disease. Since the completion of the Human
Genome Project [28], much progress has been made
regarding technological advances, the growth of in-
creased access to genomic sequencing, and the trans-
lation of gene-editing techniques into the first in-
human trials [29]. These developments have raised
the hope for treatments for rare and genetic disorders
previously considered incurable. As the prospects of
these and other new technologies continue to evolve,
many patients expect that researchers share data to
accelerate the path towards a diagnosis and ultimately
towards effective treatments. For many patients, the
benefit of research advances may come too late if
progress is not accelerated through sharing resources
and data. Researchers and ethics review boards there-
fore need to take into account the socio-ethical and
legal challenges that these developments will present
for recruitment and consent processes. Overly-rigid
Table 1 Emerging Trends in Rare Disease Research with
Consent Implications (Continued)
• Large-scale data sharing and linkage increases complexity of data
management and handling (e.g. access policies, security measures,
data coordination, use of unique personal identifiers).
Consent implications:
• Disclose information, privacy and identifiability risks to participants;
• Inform participants of sharing process and limited right to withdraw
data.
Table 2 Generic and Rare Disease Research Specific Core
Consent Elements
Generic Core Elements:
General information/Introduction (name of researchers, hospital/
institution, funders/sponsors, etc.)
Nature and objectives of the study
Voluntariness of participation
Procedures involved in participation (what will happen during the
study) /types of data and samples that will be collected
Possibility of large scale genome-wide sequencing techniques
Potential physical, psychological, social and informational risks
Potential benefits of participation
Protections in place [locally] to ensure security/privacy/confidentiality
Duration/place of data/sample storage
Hosting of data in an open access database
Access to data/samples for research purposes (who will have access,
types of access, governance framework, procedures in place – ex.
data access committee), including access by pharma/industry, if
applicable
Access to data/samples for purposes of auditing, validation, control,
etc.
Return of research results/incidental findings (processes and potential
inclusion in medical records)
Withdrawal procedures (sample/data retrieval, destruction, no further
contact, no further access, unlink, no further use, etc.)
Compensation/reimbursement
Prospects for commercialization and intellectual property procedures
Study dissemination/publication
Assent (where applicable)
Re-contact
Study oversight (IRB/REC/REB)
Core Elements (Rare Disease Research Specific):
Rare Disease Research Introductory Clause
Familial Participation
Audio/Visual Imaging
Collecting, storing, sharing of rare disease data
Recontact for matching
Data Linkage
Return of Results to Family Members
Incapacity/Death
Risks and Benefits
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interpretations of consent will be counterproductive
in the context of rare disease, to say nothing of the
fact that current consent forms have generally been
criticized for being incomprehensible to research
participants.
Conclusion
The model consent clauses presented above have been
drafted to highlight consent elements that bear in mind the
trends in rare disease research, and genomic research in
general, while providing a tool to foster harmonization and
collaborative efforts.
Limitations
The MCC Task Force recognizes the need for further guid-
ance regarding consent procedures for the recruitment of
minors (e.g., assent and re-contact at age of majority clauses)
and the nuances pertaining to the communication of results
to family members and between family members. These as-
pects were beyond the scope of the workshop.
Table 3 Model Consent Clauses for Rare Disease Research
Consent Elements: Sample Clauses:
1 Rare Disease Research
Introductory Clause
The consent information below contains special features unique to rare disease research. There is often a need to: use
audiovisual images; involve family members; share your information (inter-)nationally with clinicians and researchers;
create reference databases; and look for those who are similar. Registries and databases will be created to put all
participants and their families together so as to better understand your condition.
2 Familial Participation Information about your family history will be collected and used to interpret your results and build a family tree (also
called a “pedigree”). Creating a family tree will allow us to link or connect your personal health data with those of
your family members.
If needed, fluid or tissue samples and relevant medical history may be taken from consented family members, such as
your parents or siblings.
3 Audio/Visual Imaging Audio/ images may be taken, if necessary, as certain physical features may be associated with specific conditions. It
may also be helpful to use audiovisual imaging already taken [e.g. from your medical records and/or registries].
Often with rare disease research, the results will be used in teaching and publications. Efforts will be taken to protect
your privacy, however, the risk remains that you might be identified.
4 Collecting, storing, sharing of
data
Your collected data will be stored in databases or registries that meet security and safety standards.
Rare disease research often requires access to and the creation of large datasets. Therefore, your data will be shared
with researchers and research databases after ethics approval. Such research can take place in universities, hospitals,
non-profit groups, companies, and/or government laboratories.
Storing and sharing of data help to find people with the same condition or with similar clinical features (a process
also known as “matching”). This may also help to better understand your condition and to facilitate recruitment for
clinical trials, develop new tools, and improve diagnostics and therapies.
5 Recontact for matching Since this study includes matching, if a potential match is found, you will be notified.
[add opt-in/out option if needed]
6 Data Linkage In order to improve data completeness and to help interpret your data, we need to link your data from different
sources (e.g. medical files, administrative health databases, registries, data from family members, etc.).
7 Return of Results to Family
Members
It takes a long time to interpret research data accurately. Reports on research progress as well as general results will
be made available via […..].
Please indicate below if you wish to be notified about individual results specific to you about the rare disease in your
family.
[add opt-in/out option if needed]
If you have indicated that you wish to be notified about individual results, you will be contacted by […].
[Insert any time limitations affecting this notification].
In addition, [insert local return policy if necessary]
Due to the limitations of resources, your data may not be re-analyzed in the future.
8 Incapacity/Death Your data are important for family members and for research on your condition. Therefore, your data will be kept
and used even if you become incapacitated or die.
If you become incapacitated or die, you can name a person to be notified of results that are relevant to the health of
your family members.
[Yes (Insert name of person to be notified) / No]
9 Benefits You may or may not benefit from participating in this study. In rare disease research, because of the small sample
size, the quality of the research and the possible benefits to you and your family and others with similar conditions
requires: involving families; creating large datasets; sharing, linking and matching data; and using audio visual
images.
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